134 related articles for article (PubMed ID: 8537130)
1. Characterization of the expressed CIITA allele in the class II MHC transcriptional mutant RJ2.2.5.
Brown JA; He XF; Westerheide SD; Boss JM
Immunogenetics; 1996; 43(1-2):88-91. PubMed ID: 8537130
[No Abstract] [Full Text] [Related]
2. Transcriptional regulation of the MHC class II trans-activator (CIITA) promoter III: identification of a novel regulatory region in the 5'-untranslated region and an important role for cAMP-responsive element binding protein 1 and activating transcription factor-1 in CIITA-promoter III transcriptional activation in B lymphocytes.
van der Stoep N; Quinten E; van den Elsen PJ
J Immunol; 2002 Nov; 169(9):5061-71. PubMed ID: 12391222
[TBL] [Abstract][Full Text] [Related]
3. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).
Steimle V; Otten LA; Zufferey M; Mach B
Cell; 1993 Oct; 75(1):135-46. PubMed ID: 8402893
[TBL] [Abstract][Full Text] [Related]
4. The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element.
Brown JA; Rogers EM; Boss JM
Nucleic Acids Res; 1998 Sep; 26(18):4128-36. PubMed ID: 9722631
[TBL] [Abstract][Full Text] [Related]
5. Degradation, Promoter Recruitment and Transactivation Mediated by the Extreme N-Terminus of MHC Class II Transactivator CIITA Isoform III.
Beaulieu YB; Leon Machado JA; Ethier S; Gaudreau L; Steimle V
PLoS One; 2016; 11(2):e0148753. PubMed ID: 26871568
[TBL] [Abstract][Full Text] [Related]
6. Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression.
Long AB; Ferguson AM; Majumder P; Nagarajan UM; Boss JM
Mol Immunol; 2006 Feb; 43(5):395-409. PubMed ID: 16337482
[TBL] [Abstract][Full Text] [Related]
7. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant.
Zhou H; Su HS; Zhang X; Douhan J; Glimcher LH
J Immunol; 1997 May; 158(10):4741-9. PubMed ID: 9144488
[TBL] [Abstract][Full Text] [Related]
8. Identification of class II transcriptional activator-induced genes by representational difference analysis: discoordinate regulation of the DN alpha/DO beta heterodimer.
Taxman DJ; Cressman DE; Ting JP
J Immunol; 2000 Aug; 165(3):1410-6. PubMed ID: 10903745
[TBL] [Abstract][Full Text] [Related]
9. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5.
Scholl T; Mahanta SK; Strominger JL
Proc Natl Acad Sci U S A; 1997 Jun; 94(12):6330-4. PubMed ID: 9177217
[TBL] [Abstract][Full Text] [Related]
10. The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32.
Fontes JD; Jiang B; Peterlin BM
Nucleic Acids Res; 1997 Jun; 25(12):2522-8. PubMed ID: 9171108
[TBL] [Abstract][Full Text] [Related]
11. Combinations of dominant-negative class II transactivator, p300 or CDK9 proteins block the expression of MHC II genes.
Kanazawa S; Peterlin BM
Int Immunol; 2001 Jul; 13(7):951-8. PubMed ID: 11431425
[TBL] [Abstract][Full Text] [Related]
12. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA.
Muhlethaler-Mottet A; Otten LA; Steimle V; Mach B
EMBO J; 1997 May; 16(10):2851-60. PubMed ID: 9184229
[TBL] [Abstract][Full Text] [Related]
13. IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene.
Rohn W; Tang LP; Dong Y; Benveniste EN
J Immunol; 1999 Jan; 162(2):886-96. PubMed ID: 9916712
[TBL] [Abstract][Full Text] [Related]
14. Isolation of a B-cell-specific promoter for the human class II transactivator.
Lennon AM; Ottone C; Rigaud G; Deaven LL; Longmire J; Fellous M; Bono R; Alcaïde-Loridan C
Immunogenetics; 1997; 45(4):266-73. PubMed ID: 9002447
[TBL] [Abstract][Full Text] [Related]
15. Interplay among coactivator-associated arginine methyltransferase 1, CBP, and CIITA in IFN-gamma-inducible MHC-II gene expression.
Zika E; Fauquier L; Vandel L; Ting JP
Proc Natl Acad Sci U S A; 2005 Nov; 102(45):16321-6. PubMed ID: 16254053
[TBL] [Abstract][Full Text] [Related]
16. Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency.
Dziembowska M; Fondaneche MC; Vedrenne J; Barbieri G; Wiszniewski W; Picard C; Cant AJ; Steimle V; Charron D; Alca-Loridan C; Fischer A; Lisowska-Grospierre B
Immunogenetics; 2002 Feb; 53(10-11):821-9. PubMed ID: 11862382
[TBL] [Abstract][Full Text] [Related]
17. IFN-gamma regulation of the type IV class II transactivator promoter in astrocytes.
Dong Y; Rohn WM; Benveniste EN
J Immunol; 1999 Apr; 162(8):4731-9. PubMed ID: 10202014
[TBL] [Abstract][Full Text] [Related]
18. Mutation in the class II trans-activator leading to a mild immunodeficiency.
Wiszniewski W; Fondaneche MC; Le Deist F; Kanariou M; Selz F; Brousse N; Steimle V; Barbieri G; Alcaide-Loridan C; Charron D; Fischer A; Lisowska-Grospierre B
J Immunol; 2001 Aug; 167(3):1787-94. PubMed ID: 11466404
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator.
Radosevich M; Jager M; Ono SJ
Exp Mol Pathol; 2007 Feb; 82(1):68-76. PubMed ID: 16650406
[TBL] [Abstract][Full Text] [Related]
20. Modulation of gene expression by the MHC class II transactivator.
Nagarajan UM; Bushey A; Boss JM
J Immunol; 2002 Nov; 169(9):5078-88. PubMed ID: 12391224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
